Sandoz Creates New Global Biosimilar Unit
Sandoz has announced the creation of a new biosimilar development, manufacturing and supply unit.
Biosimilars
Sandoz Acquires Ophthalmology Franchise from Coherus
In a move to expand its ophthalmic platform, Sandoz, the former generics and biosimilars arm of Swiss drugmaker Novartis, has completed the acquisition of Coherus BioSciences’ subsidiary Coherus Ophthalmology for $170 million.
Gedeon Richter Becomes Strategic Investor of Formycon
Hungary-headquartered specialty pharmaceutical company Gedeon Richter becomes a strategic investor of German biosimilars company Formycon via cash capital increase of 9.08% of Formycon’s share capital, which corresponds to €82.84 million.
The Success Story of Biosimilars
With their triumphant advance, biosimilars are also setting in motion the usual market mechanisms. Biopharma interest groups warn against the automatic substitution of originator drugs.
CVS Health Launches Biosimilars Subsidiary Cordavis
US drugstore chain CVS Health has launched Cordavis, a wholly owned subsidiary that will collaborate with manufacturers to commercialize and co-produce biosimilar products.
Samsung Biologics and Pfizer in Biosimilars Pact
South Korean CDMO Samsung Biologics has entered into a long-term manufacturing partnership with major drugmaker Pfizer.
Novartis Definitely Plans to Spin off Sandoz
Novartis has finally confirmed definite plans to spin off its generic drugs arm Sandoz.
